The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the ...

The relationship between AL and anthracycline cardiotoxicity is unclear. In this large diverse cohort of individuals with cancer, we found that non‐Hispanic Black and Hispanic individuals had a higher ...

MELBOURNE, Australia I April 02, 2025 I Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX, Telix, the Company) today announces that a first patient has ...

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, ...

Initial data readout on track for second half of 2025HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ...

CNS Pharmaceuticals (CNSP) announced the primary analysis of its clinical trial evaluating Berubicin, the first anthracycline demonstrated to ...

The statement highlights that anthracycline chemotherapy and chest-directed radiotherapy have been well-studied cardiotoxic therapies and that modern radiotherapy, dose reductions, and use of ...

近日，北京中医药大学东直门医院王勇教授和广州中医药大学王伟教授团队在Medicine Plus上发表综述文章“Anthracycline-induced cardiotoxicity: emerging mechanisms and ...